Skip to main content

Replimune Group Inc

For the period ended Sep 30, 2024. Filed Nov 12, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 12, 2024

REPL$23.28+4.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations

(Amounts in thousands, except share and per share amounts)

Three Months Ended September 30,Six Months Ended September 30,
2024202320242023
Operating expenses:
Research and development$43,448$49,101$86,420$89,538
Selling, general and administrative15,46814,73029,86329,941
Total operating expenses58,91663,831116,283119,479
Loss from operations(58,916)(63,831)(116,283)(119,479)
Other income (expense):
Research and development incentives408443846836
Investment income5,3946,04910,10612,235
Interest expense on finance lease liability(531)(542)(1,065)(1,086)
Interest expense on debt obligations(1,438)(955)(2,864)(2,070)
Other income (expense)2,028(1,409)2,433(35)
Total other income (expense), net5,8613,5869,4569,880
Loss before income taxes$(53,055)$(60,245)$(106,827)$(109,599)
Income tax provision—$(201)$—$—
Net loss$(53,055)$(60,044)$(106,827)$(109,599)
Net loss per common share, basic and diluted$(0.68)$(0.90)$(1.45)$(1.65)
Weighted average common shares outstanding, basic and diluted78,570,13566,582,28073,903,65066,475,577
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.